09/09/2026
Plasmapheresis / therapeutic plasma exchange (TPE) is of particular interest in neurological diseases, because in some of them the problem lies not only in the nerve or muscle, but in the immune system that mistakenly attacks the body.
What exactly does it do?
Think of the blood as a transport system. The blood cells are returned to the body, while the plasma — the liquid part of the blood — is replaced.
In this way, substances such as:
abnormal autoantibodies
immune complexes
certain complement factors
inflammatory mediators are rapidly reduced in the blood.
The procedure therefore does not directly “repair” a damaged nerve. However, it reduces the immunological “hit” that may continue to damage it.
And what can this mean for movement?
It depends very much on the cause of the motor difficulty.
1. Guillain–Barré
Here plasmapheresis is one of the main treatments. It can speed up the recovery of muscle strength and walking and, in severe cases, reduce the time to recovery. European guidelines recommend therapeutic plasma exchange, usually 4–5 exchanges over 1–2 weeks, when there is severe weakness and treatment is started relatively early.
2. Myasthenia gravis
Here its effect can be particularly impressive, because autoantibodies that interfere with neuromuscular transmission are removed.
There may be an improvement in:
arm and leg strength
support and walking
swallowing
speech
respiratory muscle function.
It is mainly used when rapid improvement is needed, such as in myasthenic crisis or severe exacerbation.
3. CIDP — Chronic Inflammatory Demyelinating Polyneuropathy
In some patients, it can reduce the immune attack on peripheral nerves and improve muscle strength and function. However, the response varies greatly from person to person.
The bottom line
Plasma exchange does not create new neurons and does not immediately regenerate a damaged nerve.
However, if the weakness is due to an active immune attack, removing the abnormal antibodies can stop or reduce this attack. The body can then begin to regain neurological function as the nerves and muscles recover.
That is why diagnosis and how recent the deterioration is are of utmost importance. For example, the same treatment may be very helpful in an acute immune syndrome, but may not be of benefit in old, permanent neurological damage. The previous AAN guideline, for example, did not support plasmapheresis for chronic or secondary progressive multiple sclerosis.
Simply put:
Plasmapheresis does not directly “strengthen” muscles. It removes from the blood factors that may inhibit or damage nerve function, giving the nervous system a chance to recover.
